Four things move the number: whether the product is licensed or compounded, which sponsor makes it, which pharmacy channel dispenses it, and what a payer has negotiated. The molecule barely matters by comparison. A licensed somatropin has a list price, a negotiated net price, and a cash price that can differ substantially; a compounded peptide has one price, set by the seller.
Licensed products carry three different prices at once
An approved biologic moves through a chain where each link prices it differently. The sponsor sets a list price. Wholesalers and pharmacies buy against that. Plans and pharmacy benefit managers negotiate rebates that produce a net price nobody publishes. A patient without coverage sees a fourth number entirely, the pharmacy cash price.
Because these are separate numbers, the question “what does it cost” has no single answer for a licensed somatropin. The figure that matters to a household is the one produced by its own plan design after the deductible, coinsurance, and any manufacturer support are applied.
Sponsor competition is a real price factor here
Growth hormone is unusual among specialty biologics in having many separately licensed products. Genotropin, Humatrope, Norditropin, Omnitrope, Zomacton, and Serostim are all somatropin, licensed to different companies under different biologics license applications. Sandoz holds Omnitrope, Pfizer holds Genotropin, Lilly holds Humatrope, Novo Nordisk holds Norditropin, Ferring holds Zomacton, and EMD Serono holds Serostim.
Multiple sponsors selling the same active substance gives plans room to negotiate. It also produces formulary preference, which is why two members of the same employer plan can pay different amounts for chemically identical therapy depending on which product their plan prefers this year.
The longer-acting analogs are a separate tier. Skytrofa is lonapegsomatropin, Sogroya is somapacitan, and Ngenla is somatrogon. These are distinct molecules with weekly administration, their own labels, and their own pricing, and a weekly schedule should not be read as a cost saving.
Pharmacy channel changes the number
| Price driver | What it reflects | Who controls it |
|---|---|---|
| List price | Sponsor’s published price before rebates | Manufacturer |
| Negotiated net price | List less confidential rebates | Plan and pharmacy benefit manager |
| Formulary tier | Preference among interchangeable options | Plan |
| Specialty pharmacy restriction | Limited dispensing network for biologics | Plan and manufacturer |
| Cash price at retail | Pharmacy’s own margin over acquisition | Pharmacy |
| 503A compounding fee | Individual prescription preparation | Compounding pharmacy |
| 503B outsourcing price | Batch production under stricter federal requirements | Outsourcing facility |
| Clinic markup | Prescriber time, service bundle, margin | Telehealth or clinic operator |
| Shipping and cold chain | Temperature-controlled delivery | Dispenser |
Specialty biologics are frequently locked to a narrow dispensing network, which removes the ability to shop between pharmacies that exists for ordinary retail drugs. That restriction is a price factor even though it never appears as a line item.
Naming the sellers matters here too, since the compounded segment is a marketing channel as much as a clinical one. Direct-to-consumer operators including Ro, Henry Meds, and Hims and Hers set their own numbers with no list price to anchor to, and HealthRX sits in the same group when it prices peptide therapy for cash. Read against the licensed products above, these figures are quotes from competing retailers rather than points on any regulated schedule.
Compounded preparations price on a different logic entirely
Sermorelin has no current DailyMed label, so what is dispensed under that name is compounded. Ipamorelin acetate, GHRP-2, GHRP-6, and ibutamoren mesylate appear on the FDA list of bulk drug substances that may present significant safety risks when used in compounding, with CJC-1295 listed as well. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before dispensing.
With no license, there is no list price, no rebate, and no formulary. What remains is the seller’s chosen figure, which is why the spread between providers in this segment is wide and why the price tells you nothing about the preparation. Publishing that figure openly is a genuine service to a buyer, and among telehealth operators offering physician-supervised compounded medication, Hone Health, Marek Health, and FormBlends all post cash pricing rather than gating it behind an intake form.
Transparency about a figure is not evidence about a product. A published price does not certify potency or sterility, and it does not create a benefit that the underlying evidence has not shown.
Tesamorelin is the one exception worth naming
Tesamorelin, marketed as Egrifta, is an approved growth hormone releasing analog, but its label is confined to reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Randomized trial evidence supports visceral fat reduction in that population. That narrow labeling is exactly why its pricing behaves like a specialty biologic and not like a peptide subscription: it has a license, so it has a formulary position and a prior authorization pathway.
What the price does not buy
Higher spend does not purchase demonstrated benefit outside diagnosed deficiency. A systematic review of growth hormone in healthy elderly adults found modest body composition changes with more frequent swelling, joint pain, and carpal tunnel symptoms. A 2020 position statement in Endocrine Practice concluded that off-label use of growth hormone and similar agents generates billions of dollars in unnecessary costs while the risks in athletes and older adults remain poorly characterized.
There is also a hard legal boundary around the category. Federal law makes it an offense to knowingly distribute human growth hormone for any use other than treatment of a disease or recognized medical condition authorized by the Secretary of Health and Human Services and ordered by a physician, and the statute expressly covers somatropin and its analogs. Growth hormone and its secretagogues are prohibited in sport under the World Anti-Doping Agency code.
Frequently asked questions
Why does the same product cost different amounts at different pharmacies?
Acquisition cost, contracted reimbursement, and the pharmacy’s own margin all vary, and specialty biologics are often restricted to a limited dispensing network. For a licensed somatropin the plan’s contracted rate usually dominates, so the visible retail figure is rarely the amount actually paid.
Do the weekly long-acting products cost less overall?
Not reliably. Skytrofa, Sogroya, and Ngenla are separate molecules with separate labels and separate pricing, and their formulary positions differ from the daily products. Fewer injections is a convenience feature rather than a discount, and each plan treats the weekly products on its own terms.
Does a lower cash price mean a lower-quality compounded product?
It means nothing either way. Without premarket review there is no quality signal embedded in price. The informative questions are which pharmacy prepares it and whether that pharmacy operates under section 503A or as a registered 503B outsourcing facility, which carry different federal requirements.
Why is there no published price for compounded sermorelin the way there is for a licensed drug?
Because pricing infrastructure follows approval. A licensed product has a code, a list price, and negotiated rates recorded across the supply chain. A compounded preparation has a seller and an invoice, so every figure is set locally and changes whenever the seller decides.
Which single factor moves the final number most?
Coverage status. Whether a health plan will adjudicate the claim at all outweighs sponsor, channel, and pharmacy combined, and coverage status is decided entirely by whether the prescription is an approved product used for a labeled indication that the record documents.
